Shares of iRadimed IRMD rose 0.2% after the company reported Q1 results.
Quarterly Results
Earnings per share were up 38.46% year over year to $0.18, which beat the estimate of $0.15.
Revenue of $8,678,000 up by 2.84% from the same period last year, which missed the estimate of $9,660,000.
Guidance
iRadimed hasn't issued any earnings guidance for the time being.
iRadimed hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Apr 30, 2020
Time: 12:01 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/tcmonbty
Price Action
Company's 52-week high was at $29.74
Company's 52-week low was at $14.41
Price action over last quarter: down 18.00%
Company Overview
iRadimed Corp is a US-based company that mainly develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
